Related Experiment Videos
Erythrocyte adenosine kinase activity in gout
Clinica Chimica Acta; International Journal of Clinical Chemistry
|February 16, 1976
Summary
Erythrocyte adenosine kinase activity is significantly lower in individuals with gout compared to healthy controls. GMP reductase activity showed no significant difference between the groups, suggesting AK may play a role in gout pathogenesis.
Area of Science:
- Biochemistry
- Enzymology
- Metabolic disorders
Background:
- Gout is a metabolic disorder characterized by hyperuricemia and urate crystal deposition.
- Purine metabolism plays a crucial role in gout pathogenesis.
- Erythrocyte enzymes involved in purine metabolism are potential biomarkers for gout.
Purpose of the Study:
- To investigate erythrocyte adenosine kinase (AK) and guanosine monophosphate (GMP) reductase activities in primary gout patients.
- To determine if altered enzyme activity correlates with gout.
Main Methods:
- Adenosine kinase (AK) and guanosine monophosphate (GMP) reductase activities were measured in erythrocytes from healthy male controls and primary gout subjects.
- Enzyme activities were quantified using spectrophotometric assays and normalized to protein content.
- Statistical analysis, including t-tests, was performed to compare enzyme activities between groups.
Main Results:
- Erythrocyte adenosine kinase (AK) activity was significantly lower in gout subjects (0.615 +/- 0.128 nmol/mg protein/h) compared to controls (0.717 +/- 0.176 nmol/mg protein/h) (p < 0.05).
- No statistically significant difference was observed in erythrocyte GMP reductase activity between gout subjects (33.43 +/- 7.97 mumol/mg protein/h) and controls (30.90 +/- 6.28 mumol/mg protein/h).
Conclusions:
- Reduced erythrocyte adenosine kinase activity is associated with primary gout.
- GMP reductase activity in erythrocytes does not appear to be significantly altered in gout patients.
- Adenosine kinase may be a potential therapeutic target or biomarker in gout management.